{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:05:55Z","timestamp":1785150355417,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10557-025-07749-3","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T07:31:00Z","timestamp":1752564660000},"page":"611-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Efficacy of Inclisiran in Veneto Region (Italy): The INCLIVEN Multicenter Registry"],"prefix":"10.1007","volume":"40","author":[{"given":"Francesco","family":"Briani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Venturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bacchion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Balzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialberta","family":"Battocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"D\u2019Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Maria","family":"Frigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Licchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Rivetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Scanferlato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Zenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mugnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"7749_CR1","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","volume":"37","author":"N Townsend","year":"2016","unstructured":"Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37:3232\u201345. https:\/\/doi.org\/10.1093\/eurheartj\/ehw334.","journal-title":"Eur Heart J"},{"key":"7749_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, \u00d4unpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(04)17018-9.","journal-title":"Lancet"},{"key":"7749_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41:2313\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehz962.","journal-title":"Eur Heart J"},{"key":"7749_CR4","doi-asserted-by":"publisher","unstructured":"Garcia-Gil M, Alves-Cabratosa L, Cunillera O, Blanch J, Mart\u00ed-Lluch R, Ponjoan A, et al. Effectiveness of the low-density lipoprotein cholesterol goals in secondary cardiovascular prevention. Eur J Clin Invest. 2024. https:\/\/doi.org\/10.1111\/eci.14258.","DOI":"10.1111\/eci.14258"},{"key":"7749_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","volume":"72","author":"BA Ference","year":"2018","unstructured":"Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health. J Am Coll Cardiol. 2018;72:1141\u201356. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.046.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"7749_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"7749_CR7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokg\u00f6zo\u011flu LS, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43:830\u20133. https:\/\/doi.org\/10.1093\/eurheartj\/ehab718.","journal-title":"Eur Heart J"},{"key":"7749_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279\u201389. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047.","journal-title":"Eur J Prev Cardiol"},{"key":"7749_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health. 2023;29: 100624. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624.","journal-title":"Lancet Reg Health"},{"key":"7749_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"RS Rosenson","year":"2018","unstructured":"Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72:314\u201329. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.054.","journal-title":"J Am Coll Cardiol"},{"key":"7749_CR11","doi-asserted-by":"publisher","unstructured":"Zhang Y, Chen H, Hong L, Wang H, Li B, Zhang M, et al. Inclisiran: a new generation of lipid-lowering siRNA therapeutic. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1260921.","DOI":"10.3389\/fphar.2023.1260921"},{"key":"7749_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40256-023-00568-7","volume":"23","author":"JE Frampton","year":"2023","unstructured":"Frampton JE. Inclisiran: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2023;23:219\u201330. https:\/\/doi.org\/10.1007\/s40256-023-00568-7.","journal-title":"Am J Cardiovasc Drugs"},{"key":"7749_CR13","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1913805.","journal-title":"N Engl J Med"},{"key":"7749_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"key":"7749_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164701","volume":"11","author":"F Fogacci","year":"2022","unstructured":"Fogacci F, Giovannini M, Grandi E, Imbalzano E, Degli Esposti D, Borghi C, et al. Management of high-risk hypercholesterolemic patients and PCSK9 inhibitors reimbursement policies: data from a cohort of Italian hypercholesterolemic outpatients. J Clin Med. 2022;11: 4701. https:\/\/doi.org\/10.3390\/jcm11164701.","journal-title":"J Clin Med"},{"key":"7749_CR16","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/eurheartj\/eht015","volume":"34","author":"GK Hovingh","year":"2013","unstructured":"Hovingh GK, Davidson MH, Kastelein JJP, O\u2019Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013;34:962\u201371. https:\/\/doi.org\/10.1093\/eurheartj\/eht015.","journal-title":"Eur Heart J"},{"key":"7749_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;129:1\u201345. https:\/\/doi.org\/10.1161\/01.cir.0000437738.63853.7a.","journal-title":"Circulation"},{"key":"7749_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","volume":"16","author":"MK Cheeley","year":"2022","unstructured":"Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16:361\u201375. https:\/\/doi.org\/10.1016\/j.jacl.2022.05.068.","journal-title":"J Clin Lipidol"},{"key":"7749_CR19","doi-asserted-by":"publisher","DOI":"10.56095\/eaj.v2i1.26","author":"M Arca","year":"2023","unstructured":"Arca M, Calabr\u00f2 P, Solini A, Pirillo A, Gambacurta R, Ray KK, et al. Lipid-lowering treatment and LDL-C goal attainment in high and very high cardiovascular risk patients: evidence from the SANTORINI study-the Italian experience. European Atherosclerosis Journal. 2023. https:\/\/doi.org\/10.56095\/eaj.v2i1.26.","journal-title":"European Atherosclerosis Journal"},{"key":"7749_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.tcm.2023.08.001","volume":"34","author":"G Piazza","year":"2024","unstructured":"Piazza G, Desai NR, Baber U, Exter J, Kalich B, Monteleone P. Practical solutions for implementation of blood cholesterol guidelines in clinical practice. Trends Cardiovasc Med. 2024;34:371\u20138. https:\/\/doi.org\/10.1016\/j.tcm.2023.08.001.","journal-title":"Trends Cardiovasc Med"},{"key":"7749_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.tcm.2023.09.001","volume":"34","author":"A Bonaventura","year":"2024","unstructured":"Bonaventura A. Editorial commentary: the long and winding road to follow dyslipidemia guidelines. Trends Cardiovasc Med. 2024;34:379\u201380. https:\/\/doi.org\/10.1016\/j.tcm.2023.09.001.","journal-title":"Trends Cardiovasc Med"},{"key":"7749_CR22","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","volume":"120","author":"RS Wright","year":"2024","unstructured":"Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024;120:1400\u201310. https:\/\/doi.org\/10.1093\/cvr\/cvae109.","journal-title":"Cardiovasc Res"},{"key":"7749_CR23","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","volume":"77","author":"RS Wright","year":"2021","unstructured":"Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, et al. Pooled patient-level analysis of Inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77:1182\u201393. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.058.","journal-title":"J Am Coll Cardiol"},{"key":"7749_CR24","doi-asserted-by":"publisher","first-page":"e002184","DOI":"10.1136\/openhrt-2022-002184","volume":"9","author":"P Padam","year":"2022","unstructured":"Padam P, Barton L, Wilson S, David A, Walji S, de Lorenzo F, et al. Lipid lowering with inclisiran: a real-world single-centre experience. Open Heart. 2022;9:e002184. https:\/\/doi.org\/10.1136\/openhrt-2022-002184.","journal-title":"Open Heart"},{"key":"7749_CR25","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","volume":"112","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova U, Schatz U, Perakakis N, Kassner U, Schumann F, Axthelm C, et al. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany. Clin Res Cardiol. 2023;112:1639\u201349. https:\/\/doi.org\/10.1007\/s00392-023-02247-8.","journal-title":"Clin Res Cardiol"},{"key":"7749_CR26","doi-asserted-by":"publisher","unstructured":"Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE. First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. 2023;17:818\u201327. https:\/\/doi.org\/10.1016\/j.jacl.2023.09.005","DOI":"10.1016\/j.jacl.2023.09.005"},{"key":"7749_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.05.003","volume":"18","author":"I Naoum","year":"2024","unstructured":"Naoum I, Saliba W, Aker A, Zafrir B. Lipid-lowering therapy with inclisiran in the real-world setting: initial data from a national health care service. J Clin Lipidol. 2024;18: e809\u201316. https:\/\/doi.org\/10.1016\/j.jacl.2024.05.003.","journal-title":"J Clin Lipidol"},{"key":"7749_CR28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jacc.2024.10.106","volume":"85","author":"P Gargiulo","year":"2025","unstructured":"Gargiulo P, Marzano F, Crisci M, Marcucci R, Bruzzese D, Maloberti A, et al. Real-world efficacy and safety of inclisiran: A single-country, multicenter, observational study (CHOLINET Registry). J Am Coll Cardiol. 2025;85:536\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2024.10.106.","journal-title":"J Am Coll Cardiol"},{"key":"7749_CR29","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/dom.12536","volume":"17","author":"A Sahebkar","year":"2015","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Guerrero-Romero F, Golledge J, Watts GF. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Diabetes Obes Metab. 2015;17:1042\u201355. https:\/\/doi.org\/10.1111\/dom.12536.","journal-title":"Diabetes Obes Metab"},{"key":"7749_CR30","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1111\/dom.15650","volume":"26","author":"LA Leiter","year":"2024","unstructured":"Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, et al. Inclisiran in individuals with diabetes or obesity: post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 phase 3 randomized trials. Diabetes Obes Metab. 2024;26:3223\u201337. https:\/\/doi.org\/10.1111\/dom.15650.","journal-title":"Diabetes Obes Metab"},{"key":"7749_CR31","doi-asserted-by":"publisher","unstructured":"Mishra A, Casta\u00f1eda TR, Bader E, Elshorst B, Cummings S, Scherer P, et al. Triantennary GalNAc molecular imaging probes for monitoring hepatocyte function in a rat model of nonalcoholic steatohepatitis. Adv Sci. 2020;7https:\/\/doi.org\/10.1002\/advs.202002997","DOI":"10.1002\/advs.202002997"},{"key":"7749_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092153","volume":"20","author":"G Rega-Kaun","year":"2019","unstructured":"Rega-Kaun G, Ritzel D, Kaun C, Ebenbauer B, Thaler B, Prager M, et al. Changes of circulating extracellular vesicles from the liver after Roux-en-Y bariatric surgery. Int J Mol Sci. 2019;20: 2153. https:\/\/doi.org\/10.3390\/ijms20092153.","journal-title":"Int J Mol Sci"},{"key":"7749_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ymthe.2017.08.019","volume":"26","author":"JLS Willoughby","year":"2018","unstructured":"Willoughby JLS, Chan A, Sehgal A, Butler JS, Nair JK, Racie T, et al. Evaluation of GalNAc-siRNA conjugate activity in pre-clinical animal models with reduced asialoglycoprotein receptor expression. Mol Ther. 2018;26:105\u201314. https:\/\/doi.org\/10.1016\/j.ymthe.2017.08.019.","journal-title":"Mol Ther"},{"key":"7749_CR34","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","volume":"149","author":"F Raal","year":"2024","unstructured":"Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, et al. Efficacy, safety, and tolerability of Inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2024;149:354\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.063460.","journal-title":"Circulation"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07749-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:02:31Z","timestamp":1773698551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07749-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7749"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07749-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"2 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"The study was performed according to the Declaration of Helsinki and the local Ethics Committee approved the study protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All participants gave their consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}